Trials
Sites
Patients Enrolled
Countries

What we do
ANZUP is the leading cancer cooperative clinical trials group that brings together all of the professional disciplines and groups involved in researching and treating below the belt (penile, bladder, kidney, prostate and testicular) cancers and conduct high quality clinical research.
ANZUP identifies gaps in evidence and areas of clinical need, collaborates with the leading clinicians and researchers in below the belt cancers, and communicate frequently and effectively with the broader community along the way.



What we do
ANZUP is the leading cancer cooperative clinical trials group that brings together all of the professional disciplines and groups involved in researching and treating below the belt (penile, bladder, kidney, prostate and testicular) cancers and conduct high quality clinical research.
ANZUP identifies gaps in evidence and areas of clinical need, collaborates with the leading clinicians and researchers in below the belt cancers, and communicate frequently and effectively with the broader community along the way.



Membership
If you are not yet an ANZUP member then join our large
multidisciplinary network of urogenital and prostate cancer
researchers, clinicians, nurses, psychologists, scientists, allied
health and consumer representatives.
Membership is free and is open to anyone working in the field of
cancer care or cancer research in a professional capacity.



Trials and Research
All of the major milestones in controlling cancer worldwide have
come through clinical trials, but we still have a long way to go to
help every person affected, at risk or diagnosed with this disease.
We have clinical trials across each cancer type, in various stages
of progress: in activation, open to patient recruitment, in follow
up and completed trials.
Membership
If you are not yet an ANZUP member then join our large
multidisciplinary network of urogenital and prostate cancer
researchers, clinicians, nurses, psychologists, scientists, allied
health and consumer representatives.
Membership is free and is open to anyone working in the field of
cancer care or cancer research in a professional capacity.
Trials and Research
All of the major milestones in controlling cancer worldwide have
come through clinical trials, but we still have a long way to go to
help every person affected, at risk or diagnosed with this disease.
We have clinical trials across each cancer type, in various stages
of progress: in activation, open to patient recruitment, in follow
up and completed trials.



Membership
If you are not yet an ANZUP member then join our large
multidisciplinary network of urogenital and prostate cancer
researchers, clinicians, nurses, psychologists, scientists, allied
health and consumer representatives.
Membership is free and is open to anyone working in the field of
cancer care or cancer research in a professional capacity.



Trials and Research
All of the major milestones in controlling cancer worldwide have
come through clinical trials, but we still have a long way to go to
help every person affected, at risk or diagnosed with this disease.
We have clinical trials across each cancer type, in various stages
of progress: in activation, open to patient recruitment, in follow
up and completed trials.
Telehealth and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations, or in self-isolation due to COVID-19. Teletrials also allows trials recruitment and activity to continue.
Teleheath and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations, or in self-isolation due to COVID-19. Teletrials also allows trials recruitment and activity to continue.
Latest News



TheraP (ANZUP 1603) Clinical Trial Results in Lancet Oncology: Lutetium PSMA-617 is an alternative to Cabazitaxel Chemotherapy in Extended Follow-Up Study
This week the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) TheraP trial (ANZUP 1603) featured in The Lancet Oncology reported overall



ANZUP’s Phase 2 ENZA-p study (ANZUP 1901) interim results show a 58% reduction in the rate of PSA progression
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) today announced interim results of their Phase 2 ENZA-p (ANZUP 1901) study, which



The Cancer Australia Plan 2023-2033
The Executive Officers’ Network (EON) is a collaboration between the fourteen Cancer Cooperative Trials Groups (CCTGs) that are supported by Cancer Australia



TheraP (ANZUP 1603) Clinical Trial Results in Lancet Oncology: Lutetium PSMA-617 is an alternative to Cabazitaxel Chemotherapy in Extended Follow-Up Study
This week the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) TheraP trial (ANZUP 1603) featured in The Lancet Oncology reported overall



ANZUP’s Phase 2 ENZA-p study (ANZUP 1901) interim results show a 58% reduction in the rate of PSA progression
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) today announced interim results of their Phase 2 ENZA-p (ANZUP 1901) study, which



The Cancer Australia Plan 2023-2033
The Executive Officers’ Network (EON) is a collaboration between the fourteen Cancer Cooperative Trials Groups (CCTGs) that are supported by Cancer Australia